Joining KAI in December 2003, Ms. Okamoto-Kearney has overall development and manufacturing responsibilities and heads KAI’s lead development project, KAI-9803. Prior to KAI, Ms. Okamoto-Kearney headed product development at Corgentech, managing the lead development candidate, E2F Decoy, a drug-device combination product through Phase II and Phase III clinical trials. She managed all development, manufacturing, regulatory and quality functions as a founding employee and implemented a development growth plan leading to its current state. As Director of Project Management at Aradigm Corporation, Hayward, CA, she led a multinational drug-device development collaboration with SmithKline Beecham Pharmaceuticals and established the project management function. From 1995 to 1998, Ms. Okamoto-Kearney was a Senior Project Manager at Genentech, Inc., where she led a 4-company, multinational collaboration taking Rituxan, an anti-CD20 monoclonal antibody for the treatment of non-Hodgkins lymphoma, from Phase III development through a simultaneous US-European filing, to approval and launch beating all timeline and revenue targets. She managed projects from pre-IND through Phase III such as anti-VEGF and Herceptin at Genentech. Ms. Okamoto-Kearney spent over two years as a market analyst in the Marketing and New Product Planning department at Genentech assessing vascular and oncology drugs for the R&D portfolio and performing marketing research for tPA, the company’s flagship product. Ms. Okamoto-Kearney holds an MBA in Finance with honors from the Stern School of Business, New York University (1988) and a Masters in Biochemistry from the University of Hawaii (1983). She received her A. B. in Human Biology from Stanford University (1977).